Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101983 · ClinicalTrials.gov registry record · NA
Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT02101983 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 11 participants.
The verdict
NCT02101983, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
High-dose cytarabine (HiDAC) is considered a standard chemotherapy treatment for patients with acute myeloid leukemia. However, most patients receiving this therapy are required to be admitted to the hospital during their treatment course. The purpose of this study is to compare the safety and cost of high-dose cytarabine treatment given in an in-patient setting versus an out-patient setting.
Interventions
- DRUG Cytosine Arabinoside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-05 |
| Est. Completion | 2017-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02101983
The ClinicalTrials.gov registry entry for NCT02101983 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cytosine Arabinoside is the first listed.
NCT02101983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02101983 about?
NCT02101983 is a clinical study titled "Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)". High-dose cytarabine (HiDAC) is considered a standard chemotherapy treatment for patients with acute myeloid leukemia. However, most patients receiving this therapy are required to be admitted to the hospital during their treatment course. The purpose of this study is to compare the safety and cost...
What is the current status of trial NCT02101983?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2011-05. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02101983?
The interventions under investigation include: Cytosine Arabinoside (DRUG).
Who is sponsoring clinical trial NCT02101983?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.